name:-0.043845891952515
name:-0.016746997833252
name:-0.0187668800354
Signpath Pharma, Inc. Patent Filings

Signpath Pharma, Inc.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Signpath Pharma, Inc..The latest application filed is for "novel lipids".

Company Profile
21.33.40
  • Signpath Pharma, Inc. - Sandy UT US
  • SignPath Pharma Inc. - Quakertown PA US
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks
Patent Activity
PatentDate
Novel Lipids
App 20220056057 - McChesney; James ;   et al.
2022-02-24
Novel Lipids
App 20210198294 - McChesney; James ;   et al.
2021-07-01
Dosing Regimens for Treatment of Proliferative Disorders
App 20210161815 - Sordillo; Peter
2021-06-03
Cardiopathy-reducing phosphodiester lipids
Grant 10,975,111 - McChesney , et al. April 13, 2
2021-04-13
Suppression of Cytokine Release and Cytokine Storm
App 20200360300 - Sordillo; Peter P. ;   et al.
2020-11-19
Suppression of cytokine release and cytokine storm
Grant 10,739,353 - Sordillo , et al. A
2020-08-11
Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
Grant 10,617,639 - Helson
2020-04-14
Liposomal Mitigation of Drug-Induced Inhibition of the Cardiac IKR Channel
App 20200108056 - Helson; Lawrence ;   et al.
2020-04-09
Treatment For Glioblastoma
App 20200046652 - Sordillo; Laura A. ;   et al.
2020-02-13
Liposomal mitigation of drug-induced inhibition of the cardiac I.sub.Kr channel
Grant 10,532,045 - Helson , et al. Ja
2020-01-14
Protective Effect Of Dmpc, Dmpg, Dmpc/dmpg, Lysopg And Lysopc Against Drugs That Cause Channelopathies
App 20190388422 - Helson; Lawrence ;   et al.
2019-12-26
Novel Lipids
App 20190389888 - McChesney; James ;   et al.
2019-12-26
Treatment for glioblastoma
Grant 10,485,768 - Sordillo , et al. Nov
2019-11-26
Liposomal Mitigation of Drug-Induced Long QT Syndrome and Potassium Delayed-Rectifier Current
App 20190321293 - Helson; Lawrence
2019-10-24
Liposomal Mitigation Of Drug-induced Inhibition Of The Cardiac Ikr Channel
App 20190320975 - Helson; Lawrence ;   et al.
2019-10-24
Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
Grant 10,449,193 - Helson , et al. Oc
2019-10-22
Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
Grant 10,357,458 - Helson July 23, 2
2019-07-23
Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
Grant 10,349,884 - Helson , et al. July 16, 2
2019-07-16
Protective Effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC Against Drugs that Cause Channelopathies
App 20190167585 - Helson; Lawrence ;   et al.
2019-06-06
Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies
Grant 10,258,691 - Helson , et al.
2019-04-16
Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
Grant 10,238,602 - Helson , et al.
2019-03-26
Compositions And Method For Reducing Cardiotoxicity
App 20190008878 - Bouchard; Annie
2019-01-10
Liposomal Curcumin for Treatment of Diseases
App 20180318217 - Kurzrock; Razelle ;   et al.
2018-11-08
Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
Grant 10,117,881 - Helson November 6, 2
2018-11-06
Liposomal curcumin for treatment of diseases
Grant 10,004,687 - Kurzrock , et al. June 26, 2
2018-06-26
Protective Effect Of Dmpc, Dmpg, Dmpc/dmpg, Lysopg And Lysopc Against Drugs That Cause Channelopathies
App 20180055770 - Helson; Lawrence ;   et al.
2018-03-01
Prevention Of Drug-induced Atrio-ventricular Block
App 20170312366 - Lawrence; Helson ;   et al.
2017-11-02
Sphingosine Kinase Inhibitors And Ceramide For Maintenance Therapy Of Glioblastoma
App 20170252311 - Helson; Lawrence ;   et al.
2017-09-07
Liposomal Mitigation Of Drug-induced Long Qt Syndrome And Potassium Delayed-rectifier Current
App 20170246110 - Helson; Lawrence
2017-08-31
Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
Grant 9,682,041 - Helson June 20, 2
2017-06-20
Liposomal Mitigation Of Drug-induced Inhibition Of The Cardiac Ikr Channel
App 20170119802 - Helson; Lawrence ;   et al.
2017-05-04
Protective Effect Of Dmpc, Dmpg, Dmpc/dmpg, Lysopg And Lysopc Against Drugs That Cause Channelopathies
App 20170095489 - Helson; Lawrence
2017-04-06
Treatment For Glioblastoma
App 20170079934 - Sordillo; Laura A. ;   et al.
2017-03-23
Protective Effect Of Dmpc, Dmpg, Dmpc/dmpg, Lysopg And Lysopc Against Drugs That Cause Channelopathies
App 20170035887 - Helson; Lawrence ;   et al.
2017-02-09
Curcumin For Treating Intervertebral Disc Disease
App 20160287532 - Sordillo; Diana C. ;   et al.
2016-10-06
Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders
Grant 9,393,198 - Helson , et al. July 19, 2
2016-07-19
Liposomal Mitigation Of Drug-induced Long Qt Syndrome And Potassium Delayed-rectifier Current
App 20160193149 - Helson; Lawrence
2016-07-07
Suppression of Cytokine Release and Cytokine Storm
App 20160184330 - Sordillo; Peter P. ;   et al.
2016-06-30
Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite Tetrahydrocurcumin
App 20150377894 - Helson; Lawrence
2015-12-31
Protective Effect Of Dmpc, Dmpg, Dmpc/dmpg, Egpg, Lysopg And Lysopc Against Drugs That Cause Channelopathies
App 20150343063 - Helson; Lawrence ;   et al.
2015-12-03
Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin
Grant 9,170,257 - Helson October 27, 2
2015-10-27
Curcumin-ER, a liposomal-PLGA sustained release nanocurcumin for minimizing QT prolongation for cancer therapy
Grant 9,138,411 - Ranjan , et al. September 22, 2
2015-09-22
Curcumin-er, A Liposomal-plga Sustained Release Nanocurcumin For Minimizing Qt Prolongation For Cancer Therapy
App 20150258026 - Ranjan; Amalendu Prakash ;   et al.
2015-09-17
Liposomal Mitigation Of Drug-induced Inhibition Of The Cardiac Ikr Channel
App 20150164878 - Helson; Lawrence ;   et al.
2015-06-18
Intravenous Synthetic Curcumin (s-curcumin) For The Treatment Of Proliferative Disorders
App 20150147385 - Helson; Lawrence
2015-05-28
Liposomal Curcumin For Treatment Of Diseases
App 20140322303 - Kurzrock; Razelle ;   et al.
2014-10-30
Liposomal Mitigation Of Drug-induced Long Qt Syndrome And Potassium Delayed-rectifier Current
App 20140242156 - Helson; Lawrence
2014-08-28
Intravenous Infusion of Curcumin and a Calcium Channel Blocker
App 20140234402 - Helson; Lawrence
2014-08-21
Liposomal curcumin for treatment of diseases
Grant 8,784,881 - Kurzrock , et al. July 22, 2
2014-07-22
Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
Grant 8,753,674 - Helson June 17, 2
2014-06-17
Intravenous infusion of curcumin and a calcium channel blocker
Grant 8,747,890 - Helson June 10, 2
2014-06-10
Curcumin-er, A Liposomal-plga Sustained Release Nanocurcumin For Minimizing Qt Prolongation For Cancer Therapy
App 20140065061 - Ranjan; Amalendu Prakash ;   et al.
2014-03-06
Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite Tetrahydrocurcumin
App 20130337488 - Helson; Lawrence
2013-12-19
Liposomal Mitigation Of Drug-induced Long Qt Syndrome And Potassium Delayed-rectifier Current
App 20120308643 - Helson; Lawrence
2012-12-06
Curcumin Combination With Anti-type 2 Diabetic Drugs For Prevention And Treatment Of Disease Sequelae, Drug-related Adverse Reactions, And Improved Glycemic Control
App 20120237590 - Helson; Lawrence
2012-09-20
Intravenous Curcumin And Derivatives For Treatment Of Neurodegenerative And Stress Disorders
App 20110229555 - Helson; Lawrence ;   et al.
2011-09-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed